Related Experiment Video

Updated: Apr 17, 2026

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

8.1K

Molecular targets of luteolin in cancer

Muobarak J Tuorkey1

  • 1Zoology Department, Division of Physiology, Faculty of Science, Damanhour University, Damanhour, Egypt.

European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)
|February 26, 2015
PubMed

Insights

Luteolin, a plant compound, shows promise in fighting cancer by disrupting key cancer cell pathways. Further research is needed to fully understand its anticancer mechanisms and molecular targets.

Area of Science:

  • Phytochemistry
  • Molecular Biology
  • Cancer Research

Background:

  • Food-derived phytochemicals are a rich source of potential anticancer agents.
  • Luteolin is a well-studied compound, but its precise anticancer mechanisms and molecular targets remain unclear.
  • Understanding these mechanisms is crucial for developing novel cancer therapies.

Purpose of the Study:

  • To review existing data on luteolin's anticancer activities.
  • To propose potential molecular targets and mechanisms for luteolin's cancer-preventive action.
  • To elucidate how luteolin inhibits cancer progression or induces cancer cell death.

Main Methods:

  • Literature review of studies on luteolin and cancer.
  • Analysis of signaling pathways and transcription factors affected by luteolin.
  • Identification of potential molecular targets based on existing data.

Main Results:

  • Luteolin demonstrates significant anticancer activities.
  • Luteolin primarily functions by inactivating critical signaling and transcription pathways in cancer cells.
  • Several molecular targets and mechanisms are proposed for luteolin's effects.

Conclusions:

  • Luteolin holds potential as an anticancer agent.
  • Inactivation of essential cancer cell pathways is a key mechanism of luteolin's action.
  • Further investigation into luteolin's molecular targets will aid in cancer drug development.

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
72
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
6.4K